Mark McKenna is founder and CEO of Mirador Therapeutics, a company driving a new era in precision medicine for immune-mediated inflammatory and fibrotic diseases. He spoke with Dan Dees, co-head of Goldman Sachs Global Banking & Markets, about establishing a pace of innovation at Mirador that delivers novel medicines to patients faster. This session was filmed at our 2024 Builders and Innovators Summit.
Our weekly newsletter with insights and intelligence from across the firm
By submitting this information, you agree to receive marketing emails from Goldman Sachs and accept our privacy policy. You can opt-out at any time.